ABSTRACT
INTRODUCTION
Inherited bone marrow failure syndromes are a group of rare genetic disorders characterized by bone marrow failure, congenital anomalies, and cancer predisposition.
(1) The inherited bone marrow failure syndromes include disorders associated with pancytopenia: Fanconi anemia and dyskeratosis congenita, as well as disorders with predominantly, but not exclusively, single lineage cytopenias:
Diamond-Blackfan anemia, severe congenital neutropenia, Shwachman-Diamond syndrome, congenital amegakaryocytic thrombocytopenia, and thrombocytopenia with absent radii. (2) (3) (4) (5) (6) (7) Single disease registries, which have been established worldwide since the 1980s, are dedicated to patients diagnosed with Fanconi anemia, Diamond-Blackfan anemia, or dyskeratosis congenita (5, 8, 9) The Severe Congenital Neutropenia
International Registry differs, since it collects data on all patients with neutropenia treated with granulocyte colony stimulating factor (G-CSF). (10) These registries provide more reliable information than case series regarding clinical presentation, natural history, and response to therapy. Analysis of the data collected in the registries made it possible to evaluate the efficacy and side effects of treatments and contributed to the discovery of the causative genes. (5, (8) (9) (10) However, these registries, being diseasespecific or treatment-specific, cannot shed light on the true incidence of the various syndromes.
We established a retrospective population-based national registry of inherited bone marrow failures in Israel. Using this registry, we calculated the relative frequency of each of the inherited bone marrow failure syndromes, the birth rate of
Fanconi anemia, and the frequency of complications. Using previously described methods, we performed quantitative analysis of the risks of adverse events in Fanconi anemia. (11) (12) (13) 
DESIGN AND METHODS

Registry
Patients were registered from all 16 pediatric hematology-oncology centers in
Israel. Referral to the registry was made by the treating physician. Recruitment A research nurse (RZ) or a physician (DN) filled out the questionnaire after a review of the patients' charts at each center. The diagnosis of each patient was approved by a senior investigator (HT), based on the best available current diagnostic criteria for each disease. Only questionnaires that included sufficient data were included. Each questionnaire was individually entered into a Microsoft Excel spreadsheet.
Inclusion criteria
Fanconi anemia: individuals demonstrating an appropriate clinical picture supported by the abnormal chromosomal breakage test (2) ; and if available by mutation in one of the genes.
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Dyskeratosis congenita: individuals exhibiting the typical clinical features (15) supported when available by the presence of a mutation in the DCK1, TERT or TERC genes. (16) Diamond-Blackfan anemia: individuals fulfilling the classic diagnostic criteria, (4, 17) supported if available by increased erythrocyte adenosine deaminase (eADA) activity and/or by mutation in the RSP19, RPS24, RPS17, RPL5, RPL11 or RPL35A genes. (18) Shwachman-Diamond syndrome: individuals exhibiting neutropenia associated with exocrine pancreatic insufficiency, and, if possible, by mutation in the SBDS gene.
Severe Congenital Neutropenia: individuals with an appropriate clinical picture and, if available, by mutations in ELA2, HAX1, G6PC3 or WAS genes. (19) Congenital amegakaryocytic thrombocytopenia: individuals who presented with early-onset thrombocytopenia, typical BM findings, and mutations in the thrombopoietin receptor (cMPL) gene.
Thrombocytopenia with absent radii: individuals with typical clinical manifestations.
Bone marrow failure-not otherwise specified: individuals who presented with marrow failure and were suspected to have inherited bone marrow failure by the combination of young age at presentation, low birth weight, macrocytosis and high levels of hemoglobin F. However no specific diagnosis could be reached as there was normal chromosomal breakage test, normal telomeres length as well as no mutations in SBDS or c-MPL genes.
Hematological criteria
As previously suggested severe BMF was defined as associated with pancytopenia, necessitating SCT or causing death (12) . Diagnosis of myelodysplastic syndrome (MDS) was made by the presence of chromosomal aberration and/or 5-20% blasts in bone marrow. Since MDS does not always develop into leukemia, MDS data were analyzed separately from leukemia.
The Fanconi anemia birth rate and calculations
We estimated the Fanconi anemia birth rate using two approaches. The first was an indirect method that assumed recessive inheritance and external estimates of the frequency of any Fanconi anemia allele among Jews (1/90) (20) and non-Jews
(1/300). (21) The second was a direct approach that divided the numbers of cases enrolled in the registry according to birth year by the corresponding numbers of live births in Jews and non-Jews, respectively. (22) Statistical Methods
The follow-up period for living patients was calculated by using the date of the last follow-up at the treating medical center, minus the date of diagnosis. If the date of the last follow-up was not available, we used the date when the questionnaire was filled out. Deceased patients were censored at the time of death. Descriptive data are presented as percentages, medians, and ranges. Analyses were performed using the Microsoft Excel-XP program.
A competing risks approach to estimate cause-specific hazard functions and cumulative incidence curves for bone marrow failure, acute myeloid leukemia, and solid tumors was performed as previously described. (11) (12) (13) Fanconi anemia we also studied the association between the risk of severe bone marrow failure and leukemia and the previously identified five-item congenital abnormality scale with possible values ranging from 0 through 5. (13) Survival was described using the Kaplan-Meier method.
RESULTS Demographics
One hundred and fifty-nine living and deceased patients were registered have Fanconi anemia, 5 severe congenital neutropenia, and 3 Diamond-Blackfan anemia). Another 16 were only known by name; they were mostly family members of included patients for whom no questionnaire was filled out and they were probably lost in follow-up. The final review includes 127 patients (80%), of whom 65 were males (51%) and 62 females (49%). The earliest birth year was 1958. Demographic data are presented in Table 1 .
At the time of analysis, 89 patients (70%) were alive, 34 (27%) were dead, and 4 additional patients (all Fanconi anemia) were lost in follow-up. The youngest living patient was a 3-month-old patient with Diamond-Blackfan anemia and the oldest was a 42-year-old patient with Fanconi anemia. The median age at diagnosis was 2.2 years (range: birth to 26.5 years). The median follow-up period at the primary medical center before inclusion in the registry was 5.8 years (range: 0-39.1 years). Seventytwo (56%) patients were of Jewish origin and 55 (44%) were of Arabic origin.
Relative frequencies of the different disorders
The relative frequency of each disease is presented in Table 1 . Sixty-six (52%) Shwachman-Diamond syndrome) were initially diagnosed as having acquired aplastic anemia, the correct diagnosis was reached however, 2 and 3 years following the initial diagnosis with the appearance of dysplastic nails and exocrine pancreatic insufficiency respectively. In 2 patients (2%), although an inherited bone marrow failure syndromes was suspected, no specific diagnosis could be reached. They presented at an early age (1 and 3 years of age), to consanguineous families, they were small for gestational age and had macrocytosis as well as, high hemoglobin F levels. Normal chromosomal breakage test, normal telomeres length as well as no mutations in SBDS or c-MPL genes precluded precise diagnosis. Both are growing well with moderate pancytopenia 5-7 years following diagnosis.
Consanguinity and molecular diagnosis
Ninety-eight families were included in the registry. Consanguinity was recorded in 50 patients (40%, Table 1 ). Fifty-six patients (44%) had other affected family members; most of them were included in the registry. Eighty-six patients (68%) underwent molecular genetic testing, and pathogenic mutations were identified in 62 patients (72% of those examined) ( Table 2) .
Birth rates
The birth rate was calculated for the most common disease, Fanconi anemia.
An indirect estimate of the birth rate was obtained, assuming that the frequency of any Fanconi anemia allele is 1/90 for Jews (20) and 1/300 for other Israelis (21) Hence, the two approaches yielded similar values. These values are significantly higher than the figure of 0.28 per 100,000 based on the worldwide carrier frequency estimate of 1/300.
Overall adverse events
Adverse events evaluated included severe bone marrow failure, malignancy, and mortality. Complication details are presented in Table 3 .
Severe bone marrow failure Thirty patients (24%) developed severe bone marrow failure (as defined in reference (12), at a median age of 8 years (range: 0.5-30 years, Table 2 ). The majority of these patients (26 of the 30, 87%) had Fanconi anemia; 3 had congenital amegakaryocytic thrombocytopenia and 1 had dyskeratosis congenita. The cumulative incidence of bone marrow failure in Fanconi anemia to age 32 was 70% (Fig 1A) . The cause-specific hazard of bone marrow failure in Fanconi anemia patients peaked at 10.5%/year at age 10 years (95% CI: 6.7 -14.1%/year) ( Fig 1B) . As previously found for Fanconi anemia 12 , abnormal radii and a five-item congenital abnormality score (CABS) were together significantly associated with the risk of bone marrow failure (p = 0.009); the relative hazard for bone marrow failure increased by 1.6 for every 1-unit-increase in the CABS score (95% CI: 1.1-2.2) (data not shown).
Malignancy
Fifteen patients (15, 12%) were diagnosed with malignancy: 9 with leukemia and 6 with solid tumors (Table 3) . The majority of patients developing malignancy had Fanconi anemia (13/15), 1 had severe congenital neutropenia, and 1 had congenital amegakaryocytic thrombocytopenia. For Fanconi anemia, the O/E ratio for cancer was 71 for all cancers, similar to results from other Fanconi anemia registries (11, 13) . The cumulative incidence by age of development of cancer in Fanconi anemia, severe congenital neutropenia, and congenital amegakaryocytic thrombocytopenia is depicted in Fig 2. The probability of developing cancer by the age of 25 was 30% in Fanconi anemia and 18% for severe congenital neutropenia ( For severe congenital neutropenia the estimated cumulative incidence of AML was high, 34% at age 30.
Fifteen (15, 11.8%) patients had MDS (11, 3 severe congenital neutropenia, and 1 congenital amegakaryocytic thrombocytopenia) at the median age of 9 years (0.5-29.5). The hazard rate for MDS in Fanconi anemia was stable at 1.4%/year (95% CI: 0.76 -2.49%/year) ( Figure 1B) . The O/E ratio for MDS in Fanconi anemia was >11,000-fold.
Mortality
Thirty-four patients (27%) succumbed to their disease before inclusion in the registry (Table 3 
DISCUSSION
Accurate epidemiologic data regarding inherited bone marrow failure syndromes have been difficult to obtain and are often incomplete. The frequencies of the specific inherited bone marrow failure syndromes categories were estimated mainly from case series (4) (5) (6) (7) (8) , (10) . Our Israeli inherited bone marrow failure syndromes registry is the first population-based national study focused on the inherited bone marrow failure syndromes, including all the major rare syndromes, and it is supported in 47% of cases by molecular testing. This report is based on 127 patients with inherited bone marrow failure syndromes diagnosed in Israel between 1966 and 2007.
Studying their records enabled us to determine the relative frequency of each of these disorders, to calculate the Fanconi anemia birth rate, and to evaluate the relative frequency of complications.
By far, the most common inherited bone marrow failure syndromes was Fanconi anemia, with 66 patients (52%), followed by severe congenital neutropenia (17%) and Diamond-Blackfan anemia (14%). Congenital amegakaryocytic thrombocytopenia and dyskeratosis congenita were much less common, with 6% and 5% of patients, respectively, whereas Shwachman-Diamond syndrome and thrombocytopenia with absent radii were each found in 2% of patients (Table 1) . Only in 2 of our patients (2%) with an apparent inherited bone marrow failure syndromes were we unable to identify a specific diagnosis. The long follow-up for some of our patients and the use of molecular diagnosis may have helped provide the low number of undiagnosed inherited bone marrow failure patients in our registry.
The relatively high proportion of Fanconi anemia patients in our cohort is partially caused by the high rate of consanguinity (52% of Fanconi anemia patients, per 100,000), which is 7-fold higher than expected from the world-wide carrier frequency of 1:300. (21) The majority of our Fanconi anemia patients were either of Sephardic-Jewish extract (38%) or Israeli-Arabs (45%) and indeed, in both communities consanguinity was present ( Table 2) . Although the carrier frequency in Ashkenazi Jews is 1 in 90, that group was a minority in our Fanconi anemia families.
The most common disease in our cohort, Fanconi anemia, was also associated with the highest rate of complications and carried the worst prognosis. Severe BMF as previously defined by Rosenberg et al. (12) , developed in 30 patients with inherited bone marrow failure syndromes, 26 of whom (87%) had Fanconi anemia. As has been documented previously, Fanconi anemia is a cancer-prone disease. (11) Cancer developed in 15 of our patients, 13 of whom (87%) had Fanconi anemia. Seven of the 9 patients (78%) who developed leukemia had Fanconi anemia, and all patients with solid tumors (6) had Fanconi anemia. The cumulative incidence (Kaplan-Meier method) of cancer in Fanconi anemia was 30% by the age of 30 ( Figure 2 ) and unstable thereafter due to small numbers. The median survival rate was 35% by the same age ( Figure 3 ).
Despite the relatively small number of Fanconi anemia patients in our registry, compared with two independent and larger Fanconi anemia cohorts from other parts of the world, including the NAS and the German Fanconi Anemia Registry (GEFA), (11, 13) complications were qualitatively and quantitatively similar in all three studies. The cause-specific hazards of bone marrow failure, AML, and solid tumors (Figure 1) , the specific tumors occurring in excess and the ratios of O/E numbers of cancers were comparable. Additionally, as previously described in the NAS and the GEFA, (12, 13) a high five-item congenital abnormality score was associated with an increased BMF rate and cancer risk. The similarity between our results and those from the NAS and the GEFA supports the validity of our data.
Severe congenital neutropenia was also associated with a low actuarial median survival rate (45% at the age of 20, Figure 3 ). In contrast, Diamond-Blackfan anemia seemed to have a relatively better prognosis, since none of the patients in our cohort developed any major complications. For patients with dyskeratosis congenita, Shwachman-Diamond syndrome, congenital amegakaryocytic thrombocytopenia, and thrombocytopenia with absent radii, the number of patients is too small to draw any conclusions regarding their relative severity. Dyskeratosis congenita has also recently been documented as a cancer-prone disease,(24) and the absence of such complications in our patients is probably due to the small number of patients.
This is the first national inherited bone marrow failure syndromes registry capturing the majority of such patients in the country, having a low number of undiagnosed patients (2%), and a relatively long follow-up period (median 5.8, ranging up to 39 years). However, this study has several limitations. The registry originated in a small country and, therefore, included small numbers of patients. A high consanguinity rate may have led to an over-representation of autosomal recessive diseases. Referral bias was also present, since the data were obtained from pediatric hematology units. We may thus have underestimated patients treated primarily by an adult hematologist, and those who first presented with MDS, AML, or a solid tumor. Underestimation may also be due to under-diagnosis of patients who were never seen at the collaborating centers, or for whom data were incomplete, as well as patients who did not meet diagnostic criteria for any of the known syndromes.
In summary, our data suggest that is the most common form of inherited bone marrow failure syndromes in Israel, followed by severe congenital neutropenia and Diamond-Blackfan anemia. The Fanconi anemia population-based calculated birth rate was higher than expected, probably due to consanguinity. Fanconi anemia was associated with the worst prognosis, with a high percentage of patients developing severe BMF and cancer. Diamond-Blackfan anemia patients had the best prognosis.
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Legends to Figures DBA-Diamond-Blackfan anemia (n=18), and CAMT-congenital amegakaryocytic thrombocytopenia (n=8). The shaded areas represent the 95% point-wise confidence intervals.
